DaVita HealthCare Partners Inc (DVA)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at DaVita HealthCare Partners Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 19 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 240.10 $ — 99% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
5 of 10 Solid growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 5.5% failed
- More than 10% revenue growth is expected for the coming year 3.4% failed
- Share count grows by less than 3% a year -2.8% passed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 16.1% failed
- Gross margin at 40% or higher and without meaningful erosion 27.0% failed
- Goodwill from acquisitions does not grow faster than revenue 43.2% passed
- Net debt below twice EBITDA 4.6 x EBITDA failed
- Operating cash flow covers the profits of the last three years 3,593 m passed
- Return on capital at 15% or higher, or up versus two years ago 14.0% passed
- Insiders hold at least 10% or are net buyers 50.3% passed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 13.1% below the current price.
- Consensus
- Hold
- Analyst Ratings
- 10
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 14.88 | 14.53 – 16.03 | 14,149 | 38.0% | 6 |
| 12/31/2027 | 17.22 | 15.37 – 19.59 | 14,630 | 15.7% | 8 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- 4.01 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 3.02 | 86.10 | 3,295 | 4.70 | 7.90 | 548 | 377 |
| 2025: Q1 | 2.00 | -24.30 | 3,224 | 5.00 | 5.10 | 180 | 37 |
| 2025: Q2 | 2.58 | 2.90 | 3,380 | 6.10 | 5.90 | 324 | 203 |
| 2025: Q3 | 2.04 | -18.60 | 3,420 | 4.80 | 4.40 | 841 | 675 |
| 2025: Q4 | 2.66 | -12.00 | 3,620 | 9.90 | 6.50 | 541 | 395 |
| 2026: Q1 | 2.87 | 43.10 | 3,416 | 6.00 | 5.80 | 321 | 219 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 14,745 | 2,030 | 880 | 4.29 | 1,963 | 5,823 | 18,741 |
| 2017 | 10,877 | 1,813 | 664 | 3.47 | 1,907 | 5,897 | 18,948 |
| 2018 | 11,405 | 1,526 | 159 | 0.92 | 1,772 | 5,033 | 19,110 |
| 2019 | 11,388 | 1,643 | 811 | 5.27 | 2,072 | 3,500 | 17,311 |
| 2020 | 11,551 | 1,695 | 774 | 6.31 | 1,979 | 2,897 | 16,989 |
| 2021 | 11,619 | 1,797 | 978 | 8.90 | 1,931 | 2,371 | 17,121 |
| 2022 | 11,610 | 1,339 | 560 | 5.85 | 1,565 | 2,225 | 16,928 |
| 2023 | 12,140 | 1,603 | 692 | 7.42 | 2,059 | 2,743 | 16,894 |
| 2024 | 12,816 | 2,090 | 936 | 10.73 | 2,022 | 2,091 | 17,285 |
| 2025 | 13,643 | 2,011 | 747 | 8.48 | 1,887 | 1,158 | 17,480 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
DaVita Inc. bietet Nierendialysedienste für Patienten mit chronischem Nierenversagen in den USA an.
| Employees | 78,000 |
|---|---|
| Headquarters | Denver, CO |
| Address | 2000 16th Street, 80202 Denver, United States |
| Phone | 720 631 2100 |
| Website | davita.com |
| IPO Date | 31. Oct 1995 |
| ISIN | US23918K1088 |
| Stock Split | 2:1 on 09/09/2013 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Javier J. Rodriguez | CEO & Executive Director | 1971 |
| Joel Ackerman | CFO & Treasurer | 1965 |
| Kathleen Alyce Waters | Chief Legal & Public Affairs Officer | 1968 |
| James O. Hearty | Chief Compliance Officer | 1969 |
| David P. Maughan | Chief Operating Officer of DaVita Kidney Care | 1977 |
| Christopher Michael Berry CPA | Group VP & Chief Accounting Officer | 1975 |
| Nic Eliason | Group Vice President of Investor Relations | – |
| Stephanie Hendrickson | Chief People Officer | – |
| Misha Palecek | Chief Transformation Officer of U.S. Kidney Care Business | – |
| Jeffrey Allen Giullian | Chief Medical Officer of Kidney Care | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.